POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Potassium chloride provides potassium ions for maintaining intracellular osmolarity, acid-base balance, and nerve impulse transmission; dextrose is a carbohydrate source for energy metabolism; sodium chloride provides sodium and chloride ions for extracellular fluid balance and osmotic pressure.
| Metabolism | Potassium is primarily excreted unchanged by the kidneys; dextrose is metabolized via glycolysis and the citric acid cycle; sodium and chloride are excreted renally. |
| Excretion | Potassium: renal (90%), fecal (10%); dextrose: metabolized to CO2 and water; sodium: renal (95%). |
| Half-life | Potassium: not applicable (regulated by homeostasis); dextrose: <30 minutes; sodium: not applicable. |
| Protein binding | Potassium: negligible (<5%); dextrose: none; sodium: none. |
| Volume of Distribution | Potassium: approximately 0.5 L/kg (total body water); dextrose: distributed to total body water; sodium: mainly extracellular fluid (0.2 L/kg). |
| Bioavailability | Intravenous: 100%. |
| Onset of Action | Intravenous: immediate (within seconds to minutes). |
| Duration of Action | Depends on infusion rate and patient's potassium balance; continuous infusion required for sustained effect. |
| Molecular Weight | 74.55 |
Intravenous infusion, 1000 mL to 2000 mL per 24 hours, adjusted based on serum potassium, glucose, and sodium levels.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 30-60 mL/min: reduce potassium dose by 50% or monitor serum potassium frequently; GFR <30 mL/min: contraindicated unless serum potassium is low and monitored closely. |
| Liver impairment | No specific Child-Pugh based adjustment for potassium; dextrose may require monitoring in severe hepatic impairment due to insulin resistance. |
| Pediatric use | Weight-based: 2-4 mEq/kg/day potassium, with dextrose 5-10 mg/kg/min and sodium 2-4 mEq/kg/day, titrated to serum electrolytes. |
| Geriatric use | Elderly patients: start at low end of adult range, monitor renal function and serum electrolytes frequently due to age-related decline in renal function. |
| 1st trimester | Potassium chloride, dextrose, and sodium chloride are components of maintenance fluids and electrolyte replacement. No known teratogenic effects at recommended doses; however, use only if clearly needed due to potential electrolyte imbalances affecting maternal and fetal homeostasis. |
| 2nd trimester | Same as t1. No known fetal risks when used appropriately for electrolyte correction or maintenance. Monitor maternal electrolytes to avoid hyperkalemia or fluid overload. |
| 3rd trimester | Use with caution; may affect uterine perfusion if administered in large volumes. Avoid hyperkalemia which can cause fetal arrhythmias. Appropriate for management of dehydration or electrolyte deficits. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | All components (potassium, chloride, dextrose, sodium) cross the placenta. Potassium transfer is regulated by fetal homeostasis; excess may be cleared by fetal kidneys. Dextrose provides energy; high concentrations may cause fetal hyperglycemia and hyperinsulinemia. Sodium and chloride contribute to amniotic fluid; large volumes may affect fetal osmolality. |
| Breastfeeding | Potassium, dextrose, and sodium are normal constituents of breast milk and are not expected to cause adverse effects in nursing infants at therapeutic doses. Excretion into milk is minimal; however, monitor for signs of electrolyte imbalance if maternal doses are high or if infant has renal impairment. |
| Lactation Rating | L1: Compatible |
| Teratogenic Risk | Potassium chloride, dextrose, and sodium chloride are normal physiologic constituents. No teratogenic risk is attributed at therapeutic doses. IV administration during pregnancy is indicated for fluid and electrolyte replacement as needed. No trimester-specific risks identified. |
| Fetal Monitoring | Monitor serum potassium, glucose, sodium, and chloride levels. Assess fluid balance, urine output, and signs of hyperkalemia, hyperglycemia, or fluid overload. Fetal heart rate monitoring as clinically indicated. |
| Fertility Effects | No known adverse effects on fertility at therapeutic doses. Administration for fluid and electrolyte maintenance does not impair reproductive function. |
■ FDA Black Box Warning
Potassium chloride injection concentrate must be diluted before use; rapid infusion or undiluted administration can cause fatal hyperkalemia and cardiac arrest.
| Common Effects | fluid replacement |
| Serious Effects |
HyperkalemiaHypernatremiaHyperglycemia (for dextrose component)Severe renal impairment with oliguria or anuriaAddison's disease (uncorrected adrenal insufficiency)Crush injury or severe hemolysis (risk of hyperkalemia)Fluid overload (e.g., congestive heart failure, pulmonary edema)
| Precautions | Monitor serum potassium, glucose, and electrolytes frequently during infusion, Use with caution in patients with renal impairment, cardiac disease, or hyperkalemia, Do not administer undiluted or via rapid intravenous infusion, Risk of hyperkalemia, especially with impaired renal function, Risk of fluid overload in patients with heart failure or edema, Risk of hyperglycemia from dextrose content |
| Food/Dietary | No specific food interactions. However, patients should be aware that dietary intake of potassium (e.g., bananas, oranges, potatoes, leafy greens) and sodium (e.g., table salt, processed foods) may affect electrolyte balance. Those with renal impairment or on potassium-sparing diuretics should avoid excessive potassium-rich foods. Dextrose content may affect blood glucose; diabetic patients should monitor carbohydrate intake. |
| Clinical Pearls | This solution provides 0.22% potassium chloride (approximately 2 mEq K+ per 100 mL), which is a maintenance potassium concentration commonly used to prevent hypokalemia in patients with normal renal function. Monitor serum potassium and renal function closely, especially in patients with impaired renal function, those on potassium-sparing diuretics, or with cardiac conditions. Rate of infusion should be guided by serum potassium levels and clinical status; rapid infusion may cause hyperkalemia and cardiac arrhythmias. Use with caution in patients with severe renal impairment (oliguria, anuria) or conditions predisposing to hyperkalemia. Also note the dextrose content (5%) may cause hyperglycemia in diabetic patients; adjust insulin accordingly. The sodium chloride content (0.9%) provides isotonicity and sodium replacement; be cautious in patients with hypertension, heart failure, or edema. |
| Patient Advice | This intravenous fluid contains potassium, dextrose (sugar), and salt to help maintain your body's electrolyte and fluid balance. · Inform your healthcare provider if you have kidney problems, heart disease, diabetes, or are taking any medications, especially diuretics (water pills) or ACE inhibitors. · Tell your nurse or doctor immediately if you experience chest pain, irregular heartbeat, muscle weakness, tingling, or difficulty breathing during the infusion. · Do not adjust the infusion rate; it will be controlled by your healthcare team to ensure safety. · If you have diabetes, your blood sugar will be monitored closely as the dextrose content may affect your glucose levels. |
Loading safety data…